Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453430 | 0.89 | TSHR (0.39) | MMETSHRALDH1A1PRKCATDP1 | |
| SCHEMBL7453163 | 0.86 | MME (0.54) | MMEBIRC2TSHRCA1CA2 | |
| SCHEMBL28849031 | 0.80 | RECQL (0.41) | MMEBIRC2TSHRALDH1A1PRKCA | |
| SCHEMBL2979680 | 0.80 | MME (0.53) | MMEBIRC2CA1CA2KMT2A | |
| SCHEMBL4635107 | 0.79 | MME (0.48) | MMEBIRC2CA1CA2 | |
| SCHEMBL4635109 | 0.79 | MME (0.48) | MMEBIRC2CA1CA2 | |
| SCHEMBL1177032 | 0.79 | MME (0.58) | MMEBIRC2CA1CA2KMT2A | |
| SCHEMBL1177343 | 0.79 | MME (0.58) | MMEBIRC2CA1CA2KMT2A | |
| SCHEMBL1177029 | 0.79 | MME (0.58) | MMEBIRC2CA1CA2KMT2A | |
| SCHEMBL28665419 | 0.77 | PRKCA (0.33) | MMETSHRPRKCATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | MME 540/4885BIRC2 558/4885TSHR 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.